comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.
microlax peräruiskeliuos
mcneil / jntl consumer health (finland) oy - sodium citrate, sodium lauryl sulfoacetate, sorbitol - peräruiskeliuos - lauryylisulfaatti ja lauryylisulfaattia sisältävät yhdistelmävalmisteet
luxera 160 mg/g emulsiovoide
galderma nordic ab - methylaminolevulinas hydrochloridum - emulsiovoide - 160 mg/g - metyyliaminolevulinaatti
kalcipos-d 500 mg / 10 mikrog purutabletti
viatris oy - calcium carbonate, cholecalciferol concentrate (powder form) - purutabletti - 500 mg / 10 mikrog - kalsiumin yhdistelmävalmisteet d-vitamiinin ja/tai muiden lääkeaineiden kanssa
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
isangina 20 mg tabletti
merus labs luxco ii s.À r.l. - isosorbide mononitrate - tabletti - 20 mg - isosorbidimononitraatti
isangina 50 mg depotkapseli, kova
merus labs luxco ii s.À r.l. - isosorbide mononitrate - depotkapseli, kova - 50 mg - isosorbidimononitraatti
isangina 25 mg depotkapseli, kova
merus labs luxco ii s.À r.l. - isosorbide mononitrate - depotkapseli, kova - 25 mg - isosorbidimononitraatti
salagen 5 mg tabletti, kalvopäällysteinen
merus labs luxco ii s.À r.l. - pilocarpine hydrochloride - tabletti, kalvopäällysteinen - 5 mg - pilokarpiini
zofenil 7.5 mg tabletti, kalvopäällysteinen
menarini international operations luxembourg s.a. - zofenoprilum calcicum - tabletti, kalvopäällysteinen - 7.5 mg - tsofenopriili